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Are REM-Sleep Abnormalities in Depression more than an 
Epiphenomenon ? 
M . Berger*, D. Riemann*, M . Wiegand, D, Joy*, D. Hochli and J. Zulley (Munich) 
Introduction 
Although shortened R E M latency as an expression of R E M sleep disinhibition at the 
beginning of the night is one of the most robust biological findings in major depressive 
disorders, it has not been clarified whether it is more than an epiphenomenon. Some recent 
findings contradict the assumption that shortened R E M latencies are specific markers for 
primary or endogenous depression. For example, such abnormalities also occur in neurotic or 
situational depression (1, 2) and additionally in experimental manipulations like reduced 
behaviour activity in normal subjects (3). On the other hand, there are some arguments 
supporting the pathogenetic relevance and specificity of R E M latency shortenings in depres-
sion, especially the results of the arecoline REM-induction-test (RIT) of Gill in and Sitaram (4, 
5). They found that the direct muscarinic agonist arecoline, infused during the second non-
R E M period, could provoke a significantly more rapid onset of the following R E M period in 
acutely depressed and in remitted depressed patients compared with healthy controls. As this 
increased susceptibility of the R E M sleep regulating system to a cholinergic stimulus also 
occured in a state of psychic wellbeing, this was regarded as state independent, i.e. trait-marker 
for depression. Assuming that R E M latency is inversely related to the ratio of cholinergic to 
aminergic central nervous transmitter activities — the reciprocal interaction model postulated 
by Hobson et al. (6, 7) —, the authors interpreted these data as supporting the cholinergic/ 
aminergic imbalance hypothesis of affective disorders (8). They additionally stated that depres-
sion seems to be associated with a trait-related muscarinic supersensitivity and a state-related 
aminergic deficiency. 
This hypothesis, however, is still limited by the fact that the arecoline-RIT has not been tested 
in a larger sample of patients with different non-depressive psychiatric disorders. Furthermore, 
the procedure of the arecoline-RIT acts on the length of the second non-REM period, although 
in depression it is the first non-REM period that is shortened. Arecoline has also some marked 
experimental disadvantages that may confound results: arecoline causes unpleasant peripheral 
side-effects, making the i.m. administration of a peripheral antidote like methscopolamine 
necessary. It has only a very short half-life of maximally 30 minutes and must therefore be 
applied during sleep by infusion. Both these experimental aspects may lead to possible sleep 
disturbing effects. 
Therefore the introduction of RS 86 in sleep research by Spiegel (9) seems to provide a more 
adequate tool for testing the cholinergic hypothesis of R E M sleep abnormalities in affective 
disorders. The spiropiperidyl derivate RS 86, which passes the blood-brain barrier, is a direct, 
orally acting muscarinic agonist with a half-life of about eight hours. As it causes only minor 
peripheral side-effects, a peripheral antidote such as methscopolamine is unnecessary. It has 
already been demonstrated that RS 86 stimulates R E M sleep in healthy controls of both sexes 
and different ages (9,10). 
We therefore investigated whether the RIT with RS 86 supports the results of the arecoline-
RIT, that means reveals an increased sensitivity also of the first R E M period to this cholinergic 
stimulus in acute and remitted depressives in comparison with healthy controls. Additionally, 
we focused on the question, whether non-depressive psychiatric disorders can be differentiated 
from depressives by the RS 86-RIT, i.e., whether an abnormal RS 86-RIT is specific for 
depression. 
Study Design 
We studied 16 patients with a major depressive disorder (DSM III), six men, ten women, 
mean age 38 ± 14 years, with a mean 21-item Hamilton-scale score of 28 ± 6 and compared 
them with 16 age-and gender-matched healthy controls. 
Nine patients, three men and six women, aged 37 ± 14 years, were studied in a complete state 
of remission. They had suffered from a major depressive disorder at least half a year ago. Their 
21-item Hamilton-scale score was zero. 
Additionally we investigated 20 patients, eight men and 12 women, mean age 24 ± 5 years 
with other psychiatric disorders like anorexia nervosa (N = 6), bulimia (N = 6) obsessive 
compulsive disorder (N = 1), somatization disorder (N = 1), and personality disorders (N = 6). 
A l l subjects were drug-free for at least one week, the remitted depressives for a least four 
months. 
The RS 86-RIT was preceded by an adaptation night in the sleep lab. In depressed patients 
one placebo night preceded the night with the RS 86 application. In all other subjects the 
adaptation night was followed randomly either by the placebo night or the RS 86-RIT-night. 
A l l subjects were blind to the placebo-drug-regime. The subjects were given RS 86 in capsule 
form at 10.00 p.m. Polysomnographies were performed between 11.15 p.m. and 6.30 a.m. 
Results 
As shown in Fig. 1 RS 86 led to a highly significant shortening of the first non-REM period in 
the 16 depressives from 65.4 to 15.8 minutes. The R E M sleep shortening effect was much more 
pronounced than in the 16 healthy controls. In this group R E M latency, however, was also 
reduced significantly from 74.1 to 50.0 min. The R E M sleep cumulation curve revealed this 
R E M sleep provoking effect to be limited to the beginning of the night, although RS 86 has a 
half-life of about eight hours. Slow-wave sleep was not significantly decreased by RS 86 in 
depressives, but was reduced significantly in healthy subjects (p < 0.05). In remitted depre-
ssives, however, RS 86 only caused a nonsignificant shortening of R E M latency from 73.7 to 
64.6 min. Only two patients exhibited a R E M latency shorter than 25 min whereas the acutely 
depressed patients exhibited R E M latencies < 25 min in 14 out of 16 cases after RS 86. 
In the 20 psychiatric patients with non-depressive disorders (Fig. 2) the effect of RS 86 was 
very similar to that in healthy subjects, both in the patients with eating disorders as well as in the 
group of other psychiatric diseases. Regarding the whole patient sample there was a significant 
reduction of R E M sleep latency, which however was significantly less pronounced than in 
acutely depressed patients. 
Discussion 
Our results support the data of Gillin and Sitaram (4,5) regarding the increased susceptibility 
of the R E M sleep system to a cholinergic stimulus in depression. The RS 86-RIT, however gave 
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Fig. 1: REM latencies of 16 depressed patients and 16 age- and gender-matched healthy controls and of 9 
patients completely remitted from a major depressive disorder. Arrows mark medians. 
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Fig. 2: REM latencies of 12 patients with eating disorders and 8 patients with other non-depressive 
psychiatric diagnosis (for explanation see text). Arrows mark medians. 
no hint that such a hypersensitivity persists during remission. That means the present data are in 
agreement with the assumption of a state- but not of a trait-marker. The investigations in non-
depressed psychiatric patients seem to prove the specificity of an abnormal RIT for depression. 
Especially patients with eating disorders did not show a supersensitivity of the REM-sleep 
system to a cholinergic stimulus. It has to be mentioned, however, that those 20 patients were 
not age- and gender-matched with the depressives and that for example schizophrenic or 
schizoaffective patients were not included in the sample. 
Our data support the assumption that during depression there is a disturbance in the 
regulation of REM-sleep which seems to be promoted by cholinergic and inhibited by aminer-
gic neurons. The disinhibition of REM-sleep can be demasked by the cholinergic drug RS 86 if 
there is no REM-sleep abnormality under baseline conditions. Although this result seems to 
contradict the assumption that R E M latency shortening is only an epiphenomenon in depres-
sive disorders, the pathogenetic basis of this phenomenon is still unclear. Is it a hypersensitivity 
of muscarinic receptors during depression as Gillin and Sitaram hypothesize (4, 5), or is it the 
consequence of an impaired inhibiting effect of the aminergic systems during depression as 
Vogel (11) and Beersma et al. (12) hypothesized, based on computer simulation experiments? 
Further results in healthy subjects under conditions of experimentally induced muscarinic 
supersensitivity or impaired aminergic activity seem to be necessary to answer this question. 
Our investigation in general, however, confirms the heuristic value of the RS 86-REM-
induction test for research in depression. 
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